IDWeek 2020: Broad-spectrum antifungal drug Ibrexafungerp treats invasive fungal infections with significant effectiveness!

SCYNEXIS is a biotechnology company dedicated to overcoming and preventing refractic and drug-resistant infections, and today at IDWeek 2020, SCYNEXIS presented three posters on its new broad-spectrum antifungal drug ibrexafungerp.
poster showcases clinical and preclinical data that will highlight the potential of ibrexafungerp to fight serious and life-threatening fungal infections. Dr Nkechi Azie, vice president of
SCYNEXIS, said: "Our fight against infectious diseases is endless, with deadly fungal infections lurking in medical facilities, mainly affecting patients with weakness and immunodeficiency, claiming the lives of one million people in hospitals around the world each year.
We are committed to promoting ibrexafungerp, a new class of antifungal agents with broad-spectrum activity, including activity against two common fungi, Candida and Aspergillus, which are the cause of most fatal fungal infections."
SCYNEXIS announced on October 14 that it had submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a one-day course of oral ibrexafungerp treatment for VVC.
.